AstraZeneca Expands Study of Brilinta Against Plavix

AstraZeneca Plc is expanding studies of its blood-thinner Brilinta to patients with peripheral artery disease in an attempt to take more market share from Plavix, the world’s second-best selling drug, and its generic competitors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.